TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03432611

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-care information feature
Description: The self-care feature offers information on self-care for menstrual pain. The following topics are shown: exercise, dietary supplementation, heating pad/hot water bottle, yoga, and information on when to consult a doctor and how primary dysmenorrhoea is often treated. Notifications from the app which can be deactivated remind women of surveys and activities.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-care information feature
Description: The self-care feature offers information on self-care for menstrual pain. The following topics are shown: exercise, dietary supplementation, heating pad/hot water bottle, yoga, and information on when to consult a doctor and how primary dysmenorrhoea is often treated. Notifications from the app which can be deactivated remind women of surveys and activities.
Study: NCT00002798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study: NCT03432611

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-acupressure feature
Description: The acupressure feature offers detailed written and multimedia descriptions of an acupressure used for menstrual pain. Three acupressure points are described, which should be massaged bilaterally twice a day up to five times a day on the 5 days before menstruation and during menstruation. Each point should be massaged for 2 minutes. A timer for the acupressure and notifications from the app which can be deactivated remind women of surveys and acupressure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-acupressure feature
Description: The acupressure feature offers detailed written and multimedia descriptions of an acupressure used for menstrual pain. Three acupressure points are described, which should be massaged bilaterally twice a day up to five times a day on the 5 days before menstruation and during menstruation. Each point should be massaged for 2 minutes. A timer for the acupressure and notifications from the app which can be deactivated remind women of surveys and acupressure.
Study: NCT01340391

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omnicast
Description: dorsal splint 2-5 weeks
Study: NCT02358564

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastrointestinal Permeability Test
Description: This test will involve ingesting a solution followed by urinalysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastrointestinal Permeability Test
Description: This test will involve ingesting a solution followed by urinalysis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upper Endoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper Endoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectal Barostat and Infusion of Fats
Description: Feeding tube will be placed, as well as a small balloon in the rectum.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rectal Barostat and Infusion of Fats
Description: Feeding tube will be placed, as well as a small balloon in the rectum.
Study: NCT01742533

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human umbilical cord mesenchymal stem cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hUCMSCs and hCBMNCs

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human cord blood mononuclear cells
Study: NCT00397163

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Deflated cuff on upper arm and thigh for 20 min
Study: NCT04298060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAS181
Description: SD (4.5mg/day), HD (9mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAS181
Description: SD (4.5mg/day), HD (9mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAS181
Description: SD (4.5mg/day), HD (9mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAS181
Description: SD (4.5mg/day), HD (9mg/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 0mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 0mg/day
Study: NCT03178565

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical insufflation-exsufflation
Description: The mechanical insufflation-exsufflation device will be connected in the orotracheal tube. Four series of insufflation-exsufflation will be conducted. Each serie will be composed by 10 cycles of alternated insufflation (40 cmH2O) and exsufflation (- 40 cmH2O).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Respiratory Physiotherapy
Description: Standard chest physiotherapy will be conducted through bilateral thoracic maneuvers (percussion and vibration) followed by manual hyperinflation using a manual resuscitator bag.
Study: NCT02321735

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Quality of life questionaire
Description: Patients will participate in a QOL questionaire followed by a phone interview
Study: NCT04570540

Intervention type: DIAGNOSTIC_TEST
Intervention: Sleep Study
Description: Full-night attended in-lab polysomnography with accompanying transcutaneous capnometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Sleep Study
Description: Full-night attended in-lab polysomnography with accompanying transcutaneous capnometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Sleep Study
Description: Full-night attended in-lab polysomnography with accompanying transcutaneous capnometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary Function Test
Description: Bodyplethysmographic assessment

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary Function Test
Description: Bodyplethysmographic assessment

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary Function Test
Description: Bodyplethysmographic assessment

Intervention type: DIAGNOSTIC_TEST
Intervention: Hypercapnic ventilatory response
Description: Measurement of hypercapnic ventilatory response based on the method described by Read in 1967, using a rebreathing bag

Intervention type: DIAGNOSTIC_TEST
Intervention: Hypercapnic ventilatory response
Description: Measurement of hypercapnic ventilatory response based on the method described by Read in 1967, using a rebreathing bag

Intervention type: DIAGNOSTIC_TEST
Intervention: Hypercapnic ventilatory response
Description: Measurement of hypercapnic ventilatory response based on the method described by Read in 1967, using a rebreathing bag

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary Exercise Test
Description: Symptom-limited cardiopulmonary exercise test with a ramp protocol according to the ATS/ACCP and ERS recommendations

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary Exercise Test
Description: Symptom-limited cardiopulmonary exercise test with a ramp protocol according to the ATS/ACCP and ERS recommendations

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary Exercise Test
Description: Symptom-limited cardiopulmonary exercise test with a ramp protocol according to the ATS/ACCP and ERS recommendations
Study: NCT01691924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-509

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02774135

Intervention type: OTHER
Intervention: direct occupational therapy intervention
Description: Short term direct individual occupational therapy (9-12 weeks).Participants will receive occupational therapy intervention according to health law. The study will document the therapeutic intervention implemented in practice using the Documentation of Occupational Therapy Session during Intervention (DOTSI).
Study: NCT02902536

Intervention type: OTHER
Intervention: No interventions

Intervention type: OTHER
Intervention: No interventions

Intervention type: OTHER
Intervention: No interventions
Study: NCT00327288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imexon
Description: IV variable dosages, days 1-5 every 21 days for duration of study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: IV once every 21 days for duration of study
Study: NCT00325195

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo by intravenous infusion every 2 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegloticase
Description: 8 mg pegloticase by intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegloticase
Description: 8 mg pegloticase by intravenous infusion
Study: NCT01584206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: 10mg ezetimibe/day, at least 4 months
Study: NCT04927026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Where-there-is-no-psychiatrist Integrated Personal Therapy (WIPT)
Description: The WIPT include weekly face-to-face group sessions including mindfulness-based training and solution focused brief therapy (SFBT) involving psychoeducation and structured life review therapy catered to the personal needs of the participants.
Study: NCT03450395

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hot Cereal
Description: Intervention involves consumption of one hot cereal in the beginning of each day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot Cereal
Description: Intervention involves consumption of one hot cereal in the beginning of each day
Study: NCT04319159

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: BF-200 ALA and red light LED lamp
Description: Combination Product: Photodynamic therapy (PDT) using BF-RhodoLED® (ALA-PDT, Ameluz®-PDT).
Study: NCT02444793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05082566
Description: Part 1: PF-05082566 dose escalation; Increased doses of PF-05082566 IV are administered at appropriate intervals. Part 2: MTD of PF-05082566 IV established in Part 1 is administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-0761
Description: Part 1: KW-0761 IV administered at appropriate intervals. Part 2: KW-0761 IV administered at appropriate intervals at the MTD dose for the combination.
Study: NCT03421808

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: TMS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: TMS
Study: NCT01103466

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Atlas
Description: Altas base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
Study: NCT00002798

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study: NCT01103466

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SenSura
Description: SenSura base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
Study: NCT00002798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study: NCT04005287

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WST-057 (4% pirenzepine) Lose Dose 2mL
Description: Topical Solution
Study: NCT01103466

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conform 2
Description: Conform 2 base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
Study: NCT04030065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acid
Description: 10% Omega-3 fatty acid oil will be supplemented in intravenous form from preoperative day 1, intra-operatively (anytime during surgery before reperfusion of graft) and from post operative day 1 to day 5 in the study group. The preparation used will be 100 ml injection which contains 10 gm of Omega 3 fatty acids.
Study: NCT01374126

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate
Description: Artesunate alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin + Artesunate
Description: Combination of azithromycin + artesunate
Study: NCT00171301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: Deferasirox was administered orally once daily. Deferasirox was available as 125 mg, 250 mg, and 500 mg tablets.
Study: NCT04781101

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: Conventional therapy sessions that were planned by a physiotherapist for the children were conducted by a physiotherapist experienced in paediatrics. The therapy sessions mainly focused on functions such as the regulation of muscle tone, correction of posture, elimination of stiffness, muscle strengthening, balance/coordination training and mobilisation (Figure 2). The sessions were planned to last 40 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RoboGait®
Description: The RoboGait®-assisted gait system was used for the robot-assisted gait training. In addition to conventional therapy, 16 robot-assisted gait training sessions were conducted, each lasting 25 minutes for 2 days a week (400 minutes in total). Gait speed was 1.5 km/h in all sessions. Considering conditions such as joint limitations and spasticity, gait training was performed with patients bearing 45% to 75% of their weight.
Study: NCT02637921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxia
Description: 21 days confinement in normobaric hypoxic (FiO2 = 14%)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypoxia
Description: 21 days confinement in normobaric hypoxic (FiO2 = 14%)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ambulatory
Description: Participants hava a standardized activity level throughout the intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normoxia
Description: 21 days confinement in normobaric normoxic (FiO2 = 21%) environment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bed Rest
Description: Participants remain on supine bed rest throughout the intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bed Rest
Description: Participants remain on supine bed rest throughout the intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardised nutritional intake
Description: Macronutrient, salt and dietary energy intake will be standardized per kg body weight for each participant
Study: NCT00002798

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Study: NCT02637921

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardised nutritional intake
Description: Macronutrient, salt and dietary energy intake will be standardized per kg body weight for each participant

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardised nutritional intake
Description: Macronutrient, salt and dietary energy intake will be standardized per kg body weight for each participant
Study: NCT03816566

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: patch
Description: A standalone wearable device (the patch), that can record tracheal sounds with a microphone attached just above the suprasternal notch of the subject. The patch also has a 3-dimensional accelerometer to record body position. Furthermore, the patch records oxygen saturation using an FDA cleared pulse oximeter, Nonin 3150 WristOx2® with Bluetooth Low Energy.
Study: NCT02181426

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketorolac Dose
Description: Subjects will be assigned an enrollment number. Enrollment numbers will be assigned consecutively in the order of study enrollment. Based on the enrollment number, subjects will be randomized by a pre-determined computer randomization list created by a statistician to receive a ketorolac dose (0, 7.5, 15, 30 mg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Dose
Description: Subjects will be assigned an enrollment number. Enrollment numbers will be assigned consecutively in the order of study enrollment. Based on the enrollment number, subjects will be randomized by a pre-determined computer randomization list created by a statistician to receive a ketorolac dose (0, 7.5, 15, 30 mg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Dose
Description: Subjects will be assigned an enrollment number. Enrollment numbers will be assigned consecutively in the order of study enrollment. Based on the enrollment number, subjects will be randomized by a pre-determined computer randomization list created by a statistician to receive a ketorolac dose (0, 7.5, 15, 30 mg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Dose
Description: Subjects will be assigned an enrollment number. Enrollment numbers will be assigned consecutively in the order of study enrollment. Based on the enrollment number, subjects will be randomized by a pre-determined computer randomization list created by a statistician to receive a ketorolac dose (0, 7.5, 15, 30 mg).
Study: NCT04329897

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Software Messaging
Description: Acceptance and Commitment Therapy Delivered via an Automated Mobile Messaging Robot Mobile messages utilizing the principles of Acceptance and Commitment therapy. These messages were developed in collaboration with a pain psychologist who specializes in treating chronic pain with Acceptance and Commitment therapy. Subjects received twice-daily messages for two weeks following their orthopaedic procedure.
Study: NCT01225432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait Training
Description: 12 sessions, 30 minutes of walking on a treadmill with real time therapist directed feedback on gait kinematics.
Study: NCT03274024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ahmed Glaucoma Implant
Description: Conjunctival Flap Scleral Exposure Insertion of Episcleral Plate Priming of the tube prior to AC entrance Insertion of Tube into the Anterior Chamber Suturing tube Coverage of tube

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabeculectomy with Mitomycin C
Description: Conjunctival Flap Mitomycin C Application Scleral Flap Paracentesis Excision of Limbal Tissue Peripheral Iridectomy Scleral Flap Closure Conjunctival Flap Closure
Study: NCT02837445

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PHC ON
Description: Eligible patients randomized after optimization phase to PHC ON for 6 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PHC OFF
Description: Eligible patients randomized after optimization phase to PHC OFF for 6 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
Study: NCT00119106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil
Description: Antiretroviral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00730132

Intervention type: DRUG
Intervention: Ezetimibe
Description: Dosage determined by the investigator based on standard and applicable routine clinical practice for CHD and hypercholesterolemia patients

Intervention type: DRUG
Intervention: Statin
Description: Statin titration for the Statin Dose Titration group, and new statin treatment and dosage for the New Statin group, determined by the investigator based on standard and applicable routine clinical practice for CHD and hypercholesterolemia patients

Intervention type: DRUG
Intervention: Statin
Description: Statin titration for the Statin Dose Titration group, and new statin treatment and dosage for the New Statin group, determined by the investigator based on standard and applicable routine clinical practice for CHD and hypercholesterolemia patients
Study: NCT01626391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRx0237
Description: TRx0237 tablets 250 mg/day (given as 125 mg bid) for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets will be administered twice daily (b.i.d.) for 4 weeks. The placebo tablets include 4 mg of TRx0237 as a urinary and faecal colourant to maintain blinding; hence, the placebo group will receive a total of 8 mg/day of TRx0237.
Study: NCT01815216

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Description: Gastric bypass surgery

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain activity in resting state
Description: Measure of activity in brain networks during resting state

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain activity in resting state
Description: Measure of activity in brain networks during resting state
Study: NCT00443703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0518 (raltegravir)
Description: MK0518 (raltegravir) 400 mg by mouth (PO) twice daily (b.i.d) for up to 48 weeks of treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: KALETRA™ (lopinavir (+) ritonavir )
Description: KALETRA™ (lopinavir (+) ritonavir ) 400/100 mg by mouth (PO) twice daily (b.i.d.) for up to 48 weeks of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: placebo
Description: MK0518 (raltegravir) 400 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo
Description: KALETRA™ (lopinavir (+) ritonavir ) 400/100 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment.
Study: NCT01815216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory performance
Description: Assess concentration in 2D-location task (i.e. memory game)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Memory performance
Description: Assess concentration in 2D-location task (i.e. memory game)
Study: NCT00868985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG 3350 plus electrolytes
Description: Each patient was treated with PEG 3350 with electrolytes for 10 days at a dose of either one, two or three sachets per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG 3350 without electrolytes
Description: Each patient was treated with PEG 3350 for 10 days at a dose of either one, two or three sachets per day.
Study: NCT01742533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy
Study: NCT00587301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lap-Band
Description: Obesity and adolescents